Nanjing Vazyme Biotech (SHA:688105) partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.
Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.
The agreement is valid until March 5, 2030, the Chinese biotechnology company said.
Vazyme's shares closed over 2% higher.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。